These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18721530)

  • 1. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes.
    Müssig K; Oncü A; Lindauer P; Heininger A; Aebert H; Unertl K; Ziemer G; Häring HU; Holst JJ; Gallwitz B
    Am J Cardiol; 2008 Sep; 102(5):646-7. PubMed ID: 18721530
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of glucagon-like peptide-1 on the beta cell response to glucose-dependent insulinotropic polypeptide in elderly patients with diabetes mellitus.
    Meneilly GS; Elahi D
    J Am Geriatr Soc; 2006 Mar; 54(3):554-5. PubMed ID: 16551338
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting the incretin system in type 2 diabetes mellitus.
    Potenza M; Rayfield EJ
    Mt Sinai J Med; 2009 Jun; 76(3):244-56. PubMed ID: 19421968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects.
    Steinert RE; Poller B; Castelli MC; Friedman K; Huber AR; Drewe J; Beglinger C
    Clin Pharmacol Ther; 2009 Dec; 86(6):644-50. PubMed ID: 19727071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of incretin clinical trials.
    Garber AJ; Spann SJ
    J Fam Pract; 2008 Sep; 57(9 Suppl):S10-8. PubMed ID: 18786339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.
    Kendall DM; Cuddihy RM; Bergenstal RM
    Eur J Intern Med; 2009 Jul; 20 Suppl 2():S329-39. PubMed ID: 19580952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Incretin strategy in the treatment of type 2 diabetes mellitus--DPPIV--editorial].
    Rybka J
    Vnitr Lek; 2007 Sep; 53(9):934-5. PubMed ID: 18019660
    [No Abstract]   [Full Text] [Related]  

  • 8. [Glucagon-like peptide 1 in the treatment of patients with type 2 diabetes].
    Schmitz OE
    Ugeskr Laeger; 2007 May; 169(22):2093. PubMed ID: 17553389
    [No Abstract]   [Full Text] [Related]  

  • 9. Incretin based therapies for type 2 diabetes mellitus.
    Ghosh S; Collier A; Elhadd T; Malik I
    J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early outcomes of isolated coronary artery bypass grafting in Chinese aged patients with diabetes mellitus.
    Zhuang Y; Xiao MD; Yuan ZX; Lu CB; Lin L; Yu M; Mao JQ
    Saudi Med J; 2009 Sep; 30(9):1202-7. PubMed ID: 19750268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiopulmonary bypass increases postoperative glycemia and insulin consumption after coronary surgery.
    Knapik P; Nadziakiewicz P; Urbanska E; Saucha W; Herdynska M; Zembala M
    Ann Thorac Surg; 2009 Jun; 87(6):1859-65. PubMed ID: 19463610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
    Barnett AH
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ACCORD Trial and control of blood glucose level in type 2 diabetes mellitus: time to challenge conventional wisdom.
    Havas S
    Arch Intern Med; 2009 Jan; 169(2):150-4. PubMed ID: 19171811
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of the incretin system in the remission of type 2 diabetes following bariatric surgery.
    Mingrone G
    Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):574-9. PubMed ID: 18790374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract]   [Full Text] [Related]  

  • 17. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.
    Mannucci E; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Nov; 18(9):639-45. PubMed ID: 18849155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.
    Riedel MJ; Lee CW; Kieffer TJ
    Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E936-44. PubMed ID: 19190262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
    Malmström RE; Settergren M; Böhm F; Pernow J; Hjemdahl P
    Thromb Haemost; 2009 Jan; 101(1):157-64. PubMed ID: 19132203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based therapies in type 2 diabetes: a review of clinical results.
    Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
    Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.